Budesonide dry-powder inhalation - Dura/Spiros
Alternative Names: Budesonide Spiros; S 1320 dry-powder inhalation - Dura/SpirosLatest Information Update: 19 Dec 2021
At a glance
- Originator Dura Pharmaceuticals
- Developer Dura Pharmaceuticals; Spiros Development Corporation II
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 02 Oct 2000 Discontinued-II for Asthma in USA (Inhalation)
- 29 Aug 2000 Dura intends to discontinue development of Budesonide SpirosTM when the acquisition of Spiros Development Corporation II is completed
- 13 Jan 2000 Phase-II clinical trials for Asthma in USA (Inhalation)